Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Zevra Therapeutics Inc ZVRA

Healthcare

Zevra Therapeutics, Inc. is a rare disease company science, data, and patients need to create transformational therapies for diseases with limited or no treatment options. The Company has a diverse portfolio of products and product candidates, which includes a combination of both a clinical stage pipeline and commercial stage assets. Its pipeline includes arimoclomol, an orally delivered... see more

Add To Watchlist

Recent & Breaking News (NDAQ:ZVRA)

KemPharm, Inc. Reports Third Quarter 2016 Results

GlobeNewswire November 9, 2016

KemPharm Appeals FDA Complete Response Letter on Apadaz™ by Initiating a Formal Dispute Resolution Process

GlobeNewswire November 3, 2016

EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against KemPharm, Inc. - KMPH

PR Newswire November 1, 2016

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of KemPharm, Inc. (KMPH)

PR Newswire November 1, 2016

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Securities Fraud Violations by KemPharm, Inc. and Certain Officers and Directors

Business Wire November 1, 2016

KemPharm, Inc. to Report Third Quarter 2016 Results

GlobeNewswire November 1, 2016

Robbins Arroyo LLP is Investigating the Officers and Directors of KemPharm, Inc. (KMPH) on Behalf of Shareholders

Business Wire October 31, 2016

Lifshitz & Miller Law Firm Announces Investigation of Electronics for Imaging, Inc., Ferrellgas Partners LP, Fusion Pharm, Inc., Humana Inc., KemPharm, Inc., National Beverage Corp., Puma Biotechnology, Inc., and TG Therapeutics, Inc.

PR Newswire October 31, 2016

Johnson & Weaver, LLP Initiates Investigations of Bellerophon Therapeutics, Inc., KemPharm, Inc., Neos Therapeutics, Inc., CommVault Systems, Inc. and Resource Capital Corp.

PR Newswire October 26, 2016

KemPharm Files IND for KP201/IR, a Single-Entity Benzhydrocodone HCl Immediate Release Abuse-Deterrent Prodrug for the Treatment of Acute Pain

GlobeNewswire October 25, 2016

KemPharm Announces Licensing Agreement with Acura Pharmaceuticals for Aversion® Abuse-Deterrent Technology

GlobeNewswire October 18, 2016

KemPharm Receives Clearance from FDA to Initiate Clinical Program for KP415, an Investigational Prodrug of D-Threo-Methylphenidate for the Treatment of ADHD

GlobeNewswire October 11, 2016

Zeldes Haeggquist & Eck, LLP Announces Investigation of KemPharm, Inc.

Business Wire October 3, 2016

KemPharm Files IND for KP415 for the Treatment of ADHD, An Investigational Prodrug of D-Threo-Methylphenidate

GlobeNewswire September 19, 2016

KemPharm, Inc. Provides Corporate and Clinical Update

GlobeNewswire September 15, 2016

KemPharm to Present Data at PAINWeek 2016

GlobeNewswire September 8, 2016

KemPharm, Inc. Reports Second Quarter 2016 Results

GlobeNewswire August 10, 2016

KemPharm, Inc. to Report Second Quarter 2016 Results

GlobeNewswire August 2, 2016

KemPharm to Present at Canaccord Genuity 36th Annual Growth Conference

GlobeNewswire July 28, 2016

KemPharm Completes Key Regulatory Meetings with FDA for KP201/IR and KP415

GlobeNewswire July 14, 2016